Brogidirsen is under clinical development by Nippon Shinyaku and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData, Phase II drugs for Duchenne Muscular Dystrophy have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Brogidirsen’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Brogidirsen (NS-089) is under development for the treatment of Duchenne muscular dystrophy. It is developed based on exon skipping technology which skips exon 44 of the dystrophin gene. It is administered through parenteral and intravenous route.
Nippon Shinyaku overview
Nippon Shinyaku develops, manufactures, and sells prescribed pharmaceuticals and functional foods. The company offers products for pain, inflammation, and allergies; urological diseases; hematologic malignancies; gastrointestinal disorders; cardiovascular and metabolic diseases among others. Nippon Shinyaku also provides functional food ingredients including health food ingredients, preservatives, spices and condiments, and protein preparations. Its functional food products find application in meat processing, fish processing, dairy product, prepared food, confectionery and bakery, and beverage, among others. The company operates business through a network of offices and research laboratories located in Japan, China, the UK and the US. Nippon Shinyaku is headquartered in Minami-ku, Kyoto, Japan.
For a complete picture of Brogidirsen’s drug-specific PTSR and LoA scores, buy the report here.